2026 CCC | Phase 2 Study of Ipatasertib in Combination w/ Pembrolizumab for 1st-line Treatment of Recurrent or Metastatic Squamous Cell Cancer
0% Complete
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Aug 28, 2026
- Last Review
- Aug 28, 2026
- Expires
- Aug 28, 2029
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Accreditation
N/A
